» Articles » PMID: 10995752

Feedback Inhibition of the Retinaldehyde Dehydrogenase Gene ALDH1 by Retinoic Acid Through Retinoic Acid Receptor Alpha and CCAAT/enhancer-binding Protein Beta

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2000 Sep 21
PMID 10995752
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Aldehyde dehydrogenase 1 (ALDH1) plays a major role in the biosynthesis of retinoic acid (RA), a hormone required for several essential life processes. Recent evidence, using the aryl hydrocarbon receptor-null mouse, suggests that elevated hepatic RA down-regulates ALDH1 in a unique feedback pathway to control RA biosynthesis. To determine the mechanism of suppression of the ALDH1 gene by RA, transactivation studies were carried out in Hepa-1 mouse hepatoma cells. RA decreased expression of an ALDH1-CAT construct containing -2536 base pairs of DNA upstream of the transcription start site. Retinoic acid receptor alpha (RARalpha) transactivates the ALDH1 gene promoter through a complex with an RA response-like element (RARE) located at -91/-75 bp, which bound to the RARalpha/retinoid X receptor beta heterodimer. CCAAT/enhancer-binding protein (C/EBPbeta) also transactivates the ALDH1 gene promoter through a CCAAT box located 3' and directly adjacent to the RARE, and the ALDH1 gene is down-regulated in C/EBPbeta-null mouse liver. Exposure of Hepa-1 cells to RA results in a decrease in C/EBPbeta mRNA levels; however, there was no difference in mRNA and protein levels between wild-type and AHR-null mouse liver. These data support a model in which the RARalpha and C/EBPbeta activate the ALDH1 gene promoter through the RARE and C/EBP response elements, and in Hepa-1 cells, high levels of RA inhibit this activation by decreasing cellular levels of C/EBPbeta.

Citing Articles

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma.

Jimenez R, Constantinescu A, Yazir M, Alfonso-Triguero P, Pequerul R, Pares X Int J Mol Sci. 2024; 25(21).

PMID: 39519068 PMC: 11546810. DOI: 10.3390/ijms252111512.


Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers.

Lavudi K, Nuguri S, Olverson Z, Dhanabalan A, Patnaik S, Kokkanti R Front Cell Dev Biol. 2023; 11:1254612.

PMID: 37645246 PMC: 10461636. DOI: 10.3389/fcell.2023.1254612.


The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.

Dancik G, Varisli L, Vlahopoulos S Int J Mol Sci. 2023; 24(11).

PMID: 37298333 PMC: 10253856. DOI: 10.3390/ijms24119372.


Targeting aldehyde dehydrogenase for prostate cancer therapies.

Ma M, He W, Zhao K, Xue L, Xia S, Zhang B Front Oncol. 2022; 12:1006340.

PMID: 36300093 PMC: 9589344. DOI: 10.3389/fonc.2022.1006340.


The glucocorticoid receptor represses, whereas C/EBPβ can enhance or repress transcription.

Yoo H, Rodriguez A, You D, Lee R, Cockrum M, Grimes J iScience. 2022; 25(7):104564.

PMID: 35789854 PMC: 9249609. DOI: 10.1016/j.isci.2022.104564.